Lepissier et al quantified inflammatory markers in sputum and blood in adolescents with CF and found that levels of IL-8, IL-1β and neutrophil elastase (NE) were reduced 1 month after initiation of elexacaftor/tezacaftor/ivacaftor (ETI) therapy.34 This evidence concerns the gene CXCL8 and cystic fibrosis.